Scarica l'app Stockscreener
91.51
1.88%
1.69
Dopo l'orario di chiusura:
91.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$89.82
Aprire:
$91.18
Volume 24 ore:
6.10M
Relative Volume:
1.17
Capitalizzazione di mercato:
$283.73B
Reddito:
$58.07B
Utile/perdita netta:
$9.40B
Rapporto P/E:
30.39
EPS:
3.0113
Flusso di cassa netto:
$9.87B
1 W Prestazione:
+0.73%
1M Prestazione:
+4.61%
6M Prestazione:
+23.95%
1 anno Prestazione:
+36.22%
Intervallo 1D:
$89.70
$91.66
Intervallo di 1 settimana:
$89.67
$91.66
Portata 52W:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
Nome
Astrazeneca PLC
Settore
Industria
Telefono
44 20 3749 5000
Indirizzo
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Confronta AZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
91.51 | 278.49B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Ripresa | Jefferies | Buy |
| 2025-10-16 | Downgrade | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-02-13 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-12 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-20 | Aggiornamento | UBS | Sell → Neutral |
| 2024-11-06 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-16 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Sell |
| 2024-01-03 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-09-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-07-12 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2022-09-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Aggiornamento | Argus | Hold → Buy |
| 2022-06-14 | Downgrade | UBS | Buy → Neutral |
| 2022-02-11 | Aggiornamento | DZ Bank | Sell → Hold |
| 2021-12-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-12 | Ripresa | JP Morgan | Overweight |
| 2021-04-12 | Downgrade | Argus | Buy → Hold |
| 2021-03-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-12-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Aggiornamento | UBS | Sell → Neutral |
| 2020-11-11 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2019-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-10-25 | Aggiornamento | Liberum | Hold → Buy |
| 2019-04-02 | Downgrade | UBS | Neutral → Sell |
| 2019-02-05 | Iniziato | Exane BNP Paribas | Outperform |
| 2019-01-25 | Aggiornamento | Shore Capital | Hold → Buy |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-08-16 | Downgrade | Jefferies | Buy → Hold |
| 2018-03-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-02-06 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-05 | Reiterato | Bernstein | Outperform |
| 2018-01-18 | Reiterato | Leerink Partners | Mkt Perform |
| 2017-12-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
Mostra tutto
Astrazeneca PLC Borsa (AZN) Ultime notizie
Why is AstraZeneca PLC (AZN) One of the Best Pharma Stocks to Invest In? - Insider Monkey
AstraZeneca: A Rare Compound Growth Opportunity In Biopharma (AZN) - Seeking Alpha
Aug Ideas: Will Precidian ETFs Trust AstraZeneca PLC stock maintain strong growthJuly 2025 Sector Moves & Smart Allocation Stock Reports - BỘ NỘI VỤ
Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks - Benzinga
AstraZeneca price target raised to $105 from $95 at TD Cowen on growth outlook - Investing.com UK
AstraZeneca (AZN) Begins Phase 3 Trial of Enhertu for Ovarian Ca - GuruFocus
Quantbot Technologies LP Reduces Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Hsbc Holdings PLC - MarketBeat
Cerity Partners LLC Increases Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca (LSE:AZN): Assessing Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance
AstraZeneca PLC (NASDAQ:AZN) Nasdaq Futures Science-Driven Growth - Kalkine Media
AstraZeneca PLC ADR Rises Monday, Outperforms Market - 富途牛牛
Pillar Biosciences and AstraZeneca expand liquid biopsy access partnership to China - marketscreener.com
Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China - marketscreener.com
AstraZeneca is top pharma tip for 2026, with GSK left trailing - Proactive Investors
How Are AstraZeneca’s Scientific Initiatives Influencing Its FTSE 100 Standing? - Kalkine Media
AstraZeneca (AZN) Price Target Raised by JPMorgan - GuruFocus
First Trust Advisors LP Acquires 217,595 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Bought by Invesco Ltd. - MarketBeat
1832 Asset Management L.P. Acquires 18,543 Shares of AstraZeneca PLC $AZN - MarketBeat
Surprises Report: Is AstraZeneca PLC ZEG stock resilient in recession scenariosLong Setup & High Accuracy Investment Signals - BỘ NỘI VỤ
AstraZeneca PLC $AZN Shares Sold by Capital Fund Management S.A. - MarketBeat
AstraZeneca: An Insight Into The Growth Potential Of Imfinzi - Smartkarma
SCS Capital Management LLC Purchases 142,331 Shares of AstraZeneca PLC $AZN - MarketBeat
Marshall Wace LLP Buys 623,902 Shares of AstraZeneca PLC $AZN - MarketBeat
Guggenheim Capital LLC Has $13.58 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
UK stocks gain ahead of key US inflation data; AstraZeneca rises - marketscreener.com
Is AstraZeneca PLC (Common Stock) (ZEGA) stock a buy on weaknessWeekly Profit Summary & Fast Gain Stock Tips - Newser
Epoch Investment Partners Inc. Trims Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca selects Salesforce’s Agentforce for global HCP engagement By Investing.com - Investing.com Nigeria
Is Precidian ETFs Trust AstraZeneca PLC stock a top dividend aristocrat candidateTrade Risk Assessment & Expert Approved Momentum Trade Ideas - Newser
Why Precidian ETFs Trust AstraZeneca PLC stock benefits from AI revolutionQuarterly Investment Review & AI Enhanced Execution Alerts - Newser
Has AstraZeneca’s Strong 30% Rally Left Further Upside in 2025? - Yahoo Finance
Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement - Yahoo Finance
AstraZeneca Stake Adjustment by Capital Group - TipRanks
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Sahm
ASTRAZENECA : Bernstein remains its Buy rating - marketscreener.com
FDA Streamlines Clinical Study Requirements, Impacting AstraZene - GuruFocus
AstraZeneca (AZN) Could Benefit from FDA's Shift to Single Study Approval - GuruFocus
REGAstraZeneca PLCHolding(s) in Company - TradingView
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH - marketscreener.com
Neurimmune expands collaboration with AstraZeneca to develop and commercialize Fibril Depleter NI009 for AL Amyloidosis - marketscreener.com
AstraZeneca news live: price tests Ichimoku Kijun support — bullish momentum meets consolidation risks - Traders Union
M&T Bank Corp Has $15.30 Million Stock Position in AstraZeneca PLC $AZN - MarketBeat
J.P. Morgan Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $186.76 - 富途牛牛
AstraZeneca PLC Advances Hematology and Cell Therapy Ambition with Largest-Ever Presence at ASH - marketscreener.com
AstraZeneca (AZN) Set to Showcase Hematology Innovations at ASH 2025 - GuruFocus
New York State Common Retirement Fund Has $13.74 Million Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca to showcase hematology advances at ASH annual meeting By Investing.com - Investing.com UK
Arrowstreet Capital Limited Partnership Cuts Position in AstraZeneca PLC $AZN - MarketBeat
Guggenheim Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Raises Target Price to $206.76 - 富途牛牛
Astrazeneca PLC Azioni (AZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):